GSK CEO Emma Walmsley Files Initial Shareholding Notification
Ticker: GLAXF · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-filing, disclosure, executive-compensation
Related Tickers: GSK
TL;DR
GSK CEO Walmsley filed initial shareholding notice. Nothing to see here yet, but keep an eye on insider moves.
AI Summary
On October 10, 2024, GSK plc filed a Form 6-K reporting a transaction notification from its Chief Executive Officer, Emma Walmsley. This filing is an initial notification regarding shareholding details for a Person Discharging Managerial Responsibilities (PDMR).
Why It Matters
This filing provides transparency into the shareholdings of key executives, which can be an indicator of management's confidence in the company's future performance.
Risk Assessment
Risk Level: low — This is a routine disclosure of executive shareholding information and does not indicate any immediate financial or operational risks for the company.
Key Players & Entities
- GSK plc (company) — Registrant
- Emma Walmsley (person) — Chief Executive Officer
- 001-15170 (other) — Commission File Number
- 20241010 (date) — Filing Date
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
Who is the subject of the transaction notification?
The transaction notification is regarding Emma Walmsley, the Chief Executive Officer of GSK plc.
What is the purpose of this filing?
The purpose is to report a transaction notification concerning the shareholding details of a Person Discharging Managerial Responsibilities (PDMR).
Is this an initial notification or an amendment?
This is an initial notification.
What is the principal executive office address of GSK plc?
The principal executive office address is 79 New Oxford Street, London, WC1A 1DG.
Filing Stats: 1,814 words · 7 min read · ~6 pages · Grade level 14.7 · Accepted 2024-10-10 11:02:10
Filing Documents
- a7549h.htm (6-K) — 202KB
- 0001654954-24-012846.txt ( ) — 204KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: October 10, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc